On March 22, 2019, the European Commission’s Hearing Officer published his Activity Report for 2017-2018.[1] The Report provides key statistics on the Hearing Officer’s activity as well as a useful summary of case law on various procedural issues.
Commission Launches New Online eLeniency Tool
On March 19, 2019, the Commission introduced eLeniency, a new online tool for submitting documents and corporate statements in the
The Commission Publishes a Paper on EU Industrial Policy After Siemens/Alstom
In a March 18, 2019 paper entitled “EU industrial policy after Siemens/Alstom: Finding a New Balance Between Openness and Protection,” the Commission’s think tank, the European Political Strategy Centre, responds to the “significant backlash against EU competition policy” stemming from its prohibition of the Siemens/Alstom merger in February (reported in the EU Competition Law Newsletter of February 2019).[1]
10th Anniversary of the French Competition Authority – Results and Prospects
On March 5, 2019, the French Competition Authority celebrated its 10 years of existence. The President of the Competition Authority listed her priorities for the coming years, which include the retail sector and purchasing alliances, digital economy, “predatory” acquisitions and reflection on ex post control, as well as the labour market and labour collective agreements.
European Court of Human Rights Rules on the Admissibility of Hearsay Evidence in Cartels Cases
On February 14, 2019, the European Court of Human Rights (“ECtHR”) found in SA-Capital Oy v. Finland, that the Finnish Supreme Administrative Court had not violated SA-Capital’s right to a fair trial under Article 6 of the European Convention on Human Rights by partially relying on hearsay evidence in finding the existence and the scope of a cartel.[1] In particular, given the evidentiary complexity of cartel infringements, the ECtHR concluded that national competition authorities may use hearsay to the extent their findings do not solely depend on it.[2]
CMA vs Concordia International RX (UK)
In October 2017, the CMA obtained a warrant to enter Concordia’s (now called Advanz Pharma) business premises and search for documents relating to suspected anticompetitive behaviour in the pharmaceutical sector. Concordia applied to have the warrant discharged because it had been cooperating with the CMA’s investigation, and so there was no basis for the CMA to suspect that it would tamper with evidence.
The Council of State Upholds the Annulment of an ICA Decision Concerning a Tender for the Supply of Magnetic Resonance Devices to Healthcare Facilities
On January 14, 2019, the Council of State confirmed the first-instance court judgment and thus annulled the ICA decision,[1]
2018 Review
CMA Activity
As in 2017, the CMA leadership devoted much of 2018 to preparing for Brexit – publishing draft regulations, revising guidance, and increasing the CMA’s workforce.
2018 Year-End Review: Record Amount of Competition Fines, Cartels Fines on the Decline, Increased Practice of Pull-and-Refile in Mergers
The Commission issued fines totaling €6.5 billion in 2018, which is a new record and almost double the amount of competition fines in 2017.
2018 Year-end Review: Record Amount of Competition Fines, Cartels Fines on the Decline, Increased Practice of Pull-and-Refile in Mergers
The Commission issued fines totaling €6.5 billion in 2018, which is a new record and almost double the amount of competition fines in 2017.